Combined administration of testosterone plus an ornithine decarboxylase inhibitor as a selective prostate-sparing anabolic therapy.
Jasuja R, Costello JC, Singh R, Gupta V, Spina CS, Toraldo G, Jang H, Li H, Serra C, Guo W, Chauhan P, Narula NS, Guarneri T, Ergun A, Travison TG, Collins JJ, Bhasin S.
Jasuja R, et al. Among authors: spina cs.
Aging Cell. 2014 Apr;13(2):303-10. doi: 10.1111/acel.12174. Epub 2013 Dec 4.
Aging Cell. 2014.
PMID: 24305501
Free PMC article.